These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 11395856)

  • 21. Improving the efficacy of preoperative autologous blood donation in patients with low hematocrit: a randomized, double-blind, controlled trial of recombinant human erythropoietin.
    Price TH; Goodnough LT; Vogler WR; Sacher RA; Hellman RM; Johnston MF; Bolgiano DC; Abels RI
    Am J Med; 1996 Aug; 101(2A):22S-27S. PubMed ID: 8928704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythropoietin in Glaucoma: From Mechanism to Therapy.
    Lai YF; Lin TY; Chen YH; Lu DW
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
    Wilhelm-Leen ER; Winkelmayer WC
    Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythropoietin--a novel concept for neuroprotection.
    Sirén AL; Ehrenreich H
    Eur Arch Psychiatry Clin Neurosci; 2001 Aug; 251(4):179-84. PubMed ID: 11697582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Derivatives of erythropoietin that are tissue protective but not erythropoietic.
    Leist M; Ghezzi P; Grasso G; Bianchi R; Villa P; Fratelli M; Savino C; Bianchi M; Nielsen J; Gerwien J; Kallunki P; Larsen AK; Helboe L; Christensen S; Pedersen LO; Nielsen M; Torup L; Sager T; Sfacteria A; Erbayraktar S; Erbayraktar Z; Gokmen N; Yilmaz O; Cerami-Hand C; Xie QW; Coleman T; Cerami A; Brines M
    Science; 2004 Jul; 305(5681):239-42. PubMed ID: 15247477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotective properties of a novel, non-haematopoietic agonist of the erythropoietin receptor.
    Pankratova S; Kiryushko D; Sonn K; Soroka V; Køhler LB; Rathje M; Gu B; Gotfryd K; Clausen O; Zharkovsky A; Bock E; Berezin V
    Brain; 2010 Aug; 133(Pt 8):2281-94. PubMed ID: 20435631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoietin 2nd cerebral protection after acute injuries: a double-edged sword?
    Velly L; Pellegrini L; Guillet B; Bruder N; Pisano P
    Pharmacol Ther; 2010 Dec; 128(3):445-59. PubMed ID: 20732352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of erythropoietin in brain homeostasis, neurodevelopment and neuroprotection].
    Kocsis I; Treszl A; Vásárhelyi B
    Orv Hetil; 2005 Dec; 146(50):2527-32. PubMed ID: 16440497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hematopoietic growth factor EPO has neuro-protective and neuro-trophic effects--review].
    Zhou ZY; Yang M; Fok TF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Apr; 13(2):332-7. PubMed ID: 15854305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers.
    Wu G; Wadgymar A; Wong G; Ting R; Nathoo B; Mendelssohn D; Pandeya S; Sapir D; Tam P
    Am J Kidney Dis; 2004 Aug; 44(2):264-9. PubMed ID: 15264184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythropoietin in Optic Neuropathies: Current Future Strategies for Optic Nerve Protection and Repair.
    Lai YF; Lin TY; Ho PK; Chen YH; Huang YC; Lu DW
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evolving role of epoetin alfa in cancer therapy.
    Henry DH
    Oncologist; 2004; 9(1):97-107. PubMed ID: 14755019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging and serum biomarkers reflecting the functional efficacy of extended erythropoietin treatment in rats following infantile traumatic brain injury.
    Robinson S; Winer JL; Berkner J; Chan LA; Denson JL; Maxwell JR; Yang Y; Sillerud LO; Tasker RC; Meehan WP; Mannix R; Jantzie LL
    J Neurosurg Pediatr; 2016 Jun; 17(6):739-55. PubMed ID: 26894518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroprotective effects of erythropoietin pretreatment in a rodent model of transient middle cerebral artery occlusion.
    Ratilal BO; Arroja MM; Rocha JP; Fernandes AM; Barateiro AP; Brites DM; Pinto RM; Sepodes BM; Mota-Filipe HD
    J Neurosurg; 2014 Jul; 121(1):55-62. PubMed ID: 24702327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases.
    Merelli A; Czornyj L; Lazarowski A
    Int J Neurosci; 2015; 125(11):793-7. PubMed ID: 25405533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epoetin alfa. Clinical evolution of a pleiotropic cytokine.
    Henry DH; Bowers P; Romano MT; Provenzano R
    Arch Intern Med; 2004 Feb; 164(3):262-76. PubMed ID: 14769622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term results of enriched environment and erythropoietin after hypobaric hypoxia in rats.
    Hralová M; Angerová Y; Gueye T; Bortelová J; Svestková O; Zima T; Lippertová-Grünerová M
    Physiol Res; 2013; 62(4):463-70. PubMed ID: 23590602
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.